Abstract:Background: Zinc finger protein 500 (ZNF500) has an unknown expression pattern and biological function in human tissues. This study was designed to determine what role ZNF500 played in breast cancer progression and chemotherapy resistance. Methods: Firstly, we assessed the expression pattern of ZNF500 by bioinformatics assay and immunohistochemistry staining. Colony formation assay, MTT assay, EdU assay, flow cytometric analysis, western blotting analysis, mice xenograft model, immunofluorescence assay, RT-PCR, PCR-array, GST-pull down assay and immunoprecipitation assay were performed to investigate the effect of ZNF500 on proliferation, chemotherapy sensitivity and P53-P21-E2F4 signaling axis activation. Secondly, we constructed ZNF500-ΔC2H2, ZNF500-ΔSCAN,ZNF500-ΔKRAB, P53-ΔC, P53-ΔDBD, P53-ΔN mutant plasmids. Immunoprecipitation assay, GST-pull down assay, and western blotting analysis were performed to evaluate interaction among ZNF500, P53 and MDM2, as well as their impact on chemotherapy sensitivity. Finally, immunohistochemistry analysis was used to assess the expression of ZNF500, P53 and E2F4 in clinical tissue samples and its correlation with chemotherapy resistance. Results: We found that ZNF500 was highly expressed in breast cancer, but negatively correlated with advanced TNM stage, lymph node metastasis and poor prognosis. ZNF500 overexpression abolished in vivo and in vitro breast cancer cell proliferation by activating the p53-p21-E2F4 signaling axis and directly interacted with p53 via its C2H2 domain. This may prevent ubiquitination of p53 in a manner that is competitive to MDM2, thus stabilizing p53. When ZNF500-∆C2H2 was overexpressed, suppressed proliferation of breast cancer cells was neutralized in vitro and in vivo . In human breast cancer tissues, ZNF500 expression was positively correlated with p53and E2F4 expression. ZNF500 expression was significantly lower in patients with Miller/Payne Grade 1–2 than that in those with Miller/PayneGrade 3–5. Conclusions: Our data suggest that ZNF500 can directly bind to the C-terminal of p53 via its C2H2 domain. This interaction may prevent ubiquitin-mediated degradation by MDM2, thus abrogating the proliferation of breast cancer cells, strengthening DNA damage, and sensitizing breast cancer patients to chemotherapy.

Profilin 1 Potentiates Apoptosis Induced by Staurosporine in Cancer Cells

Profilin1 Facilitates Staurosporine-Triggered Apoptosis By Stabilizing The Integrin Beta 1-Actin Complex In Breast Cancer Cells

Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis

Profilin1 Sensitizes Pancreatic Cancer Cells to Irradiation by Inducing Apoptosis and Reducing Autophagy

A balanced level of profilin-1 promotes stemness and tumor-initiating potential of breast cancer cells

STC1 Promotes Cell Apoptosis Via NF-κB Phospho-P65 Ser536 in Cervical Cancer Cells

P53 Transcription-Dependent and -Independent Regulation of Cerebellar Neural Precursor Cell Apoptosis

Inhibition of AKT/FoxO3a signaling induced PUMA expression in response to p53-independent cytotoxic effects of H1: A derivative of tetrandrine.

Stathmin, Interacting with Nf-κB, Promotes Tumor Growth and Predicts Poor Prognosis of Pancreatic Cancer

Porcine ubiquitin-like protein MNSFβ promotes cell apoptosis and covalently binds to BCL-G to enhance staurosporine-induced apoptosis

Effect of targeted mammalian sterile 20-like kinase 1 regulation on proliferation and apoptosis of SW480 colorectal cancer cells

MST1 Promotes Apoptosis Through Regulating Sirt1-dependent P53 Deacetylation*

Protease Nexin 1 Induces Apoptosis of Prostate Tumor Cells Through Inhibition of X-Chromosome-Linked Inhibitor of Apoptosis Protein

FKBP51 induces p53-dependent apoptosis and enhances drug sensitivity of human non-small-cell lung cancer cells.

Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway

Stabilization of P53 is a Novel Mechanism for Proapoptotic Function of NF-κB

Epigenetic Silencing Of Aspp1 Confers 5-Fu Resistance In Clear Cell Renal Cell Carcinoma By Preventing P53 Activation

Physical and Functional Antagonism between Tumor Suppressor Protein p53 and Fortilin, an Anti-apoptotic Protein

Fstl1 Contributes To Tumor Progression Via Attenuating Apoptosis In A Akt/Gsk-3 Beta Dependent Manner In Hepatocellular Carcinoma

ZNF500 Suppresses the Proliferation of Breast Cancer Cells and Sensitizes Them to Chemotherapy by Stabilizing P53 in a Manner That is Competitive to MDM2

Synergistic Tumor Suppression by Coexpression of FUS1 and P53 is Associated with Down-Regulation of Murine Double Minute-2 and Activation of the Apoptotic Protease-Activating Factor 1-Dependent Apoptotic Pathway in Human Non-Small Cell Lung Cancer Cells.